(Q44630730)

English

Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation

scientific article published in November 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Adriano Venditti

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Francesco Buccisano

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Paolo de Fabritiis

9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

author name string

Maurillo L

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Del Poeta G

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Mazzone C

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Tamburini A

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Del Principe MI

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Consalvo MI

8

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Cudillo L

10

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Picardi A

11

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Franchi A

12

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Lo-Coco F

13

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Amadori S

14

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

publication date

1 November 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

2178-2182

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403138

0 references

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403138

21 January 2018

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403138

21 January 2018

Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an adult treater's view

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403138

21 January 2018

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403138

21 January 2018

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403138

21 January 2018

Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403138

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403138

7 January 2021

based on heuristic

inferred from DOI database lookup

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403138

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403138

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403138

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403138

7 January 2021

based on heuristic

inferred from DOI database lookup

How long can we give interleukin-2? Clinical and immunological evaluation of AML patients after 10 or more years of IL2 administration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403138

7 January 2021

based on heuristic

inferred from DOI database lookup

The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403138

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2403138

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44630730&oldid=2098839505"